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Abstract: Cardiovascular disease (CVD) remains the top cause of global mortality. There 
is considerable evidence that supports the mortality and morbidity benefit of statin therapy in 
coronary heart disease (CHD) and stroke, both in primary and secondary prevention settings. 
Data also exist pointing to the advantage of statin treatment in other high-risk CVD   conditions, 
such as diabetes, CKD, CHF, and PVD. National and international clinical guidelines in the 
management of these CVD conditions all advocate for the utilization of statin therapy in 
  appropriate patients. However, overall compliance to statin therapy remains suboptimal. Patient-, 
physician-, and economic-related factors all play a role. These factors need to be considered 
in devising approaches to enhance adherence to guideline-based therapies. To fully reap the 
benefits of statin therapy, interventions which improve long-term treatment compliance in real-
world settings should be encouraged.
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Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting 
for nearly 30% of the annual global mortality.1 In the United States, where the disease 
is highly prevalent, over one third of the population has one or more types of CVD. 
Coronary heart disease (CHD) affects nearly 18 million Americans. As the predominant 
cause of death from CVD, it is estimated that over one million individuals suffer from 
acute CHD events each year in the United States. Stroke, the second leading cause 
of death from CVD, has a prevalence of nearly 6.5 million, and over 600,000 new 
stroke cases are diagnosed annually in the United States.2 Other forms of high-risk 
CVD conditions are common as well. Approximately 5 million Americans have been 
diagnosed with heart failure (HF), and around 8 million Americans with peripheral vas-
cular disease (PVD). Diabetes mellitus, a major CVD risk factor and CHD-equivalent, 
afflicts approximately 5.5 million individuals in the United States.
Dyslipidemia is one of the major CVD risk factors, and cholesterol-modifying 
therapy has well-established benefits in the primary and secondary prevention of 
CHD and stroke. As such, lipid-lowering therapy, primarily with the HMG-CoA-
reductase inhibitors (statins), has become the mainstay of therapeutic guidelines for 
the   management of these conditions.3,4 There is also a growing body of evidence 
supporting the benefit of statin therapy in other CVD conditions such as heart failure 
(HF), PVD, and chronic kidney disease (CKD). Furthermore, statin therapy has already 
been an integral part of the standard management of diabetes mellitus, a major CVD 
risk   factor and CHD-equivalent.5Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Although the burden of CVD remains high, mortality 
has been on a declining trend, which is largely attributed 
to   evidence-based therapies – especially risk-reduction 
  strategies, including the use of statins. Despite the known 
benefits, however, a significant proportion of high risk 
patients with CVD still do not receive the recommended 
regimens of lipid-modifying therapy, and many others 
  discontinue treatment after being initiated on statin therapy. 
Improving the compliance to guideline-based therapies by 
both patients and physicians could potentially further reduce 
the public health and economic burden imposed by CVD.
Lipids, CVD risk, and statins
The relationship between abnormal plasma cholesterol 
  fractions and increased CVD risk was described up to 
60 years ago, when the role of the different lipoproteins 
in atherosclerosis was just being elucidated.6 The modern 
concept of atherogenesis highlights the crucial roles these 
lipoproteins play in the atherosclerotic process. One of the 
earliest steps in atheroma formation involves the infiltration 
of the dysfunctional vascular endothelium by low-density 
lipoprotein cholesterol (LDL), the most atherogenic of the 
lipoproteins. The LDL in the vessel wall becomes oxidized 
and is taken up by macrophages forming the classic foam 
cells. This process further stimulates lipid deposition and 
incites the inflammatory cascade that leads to the formation 
of the atherosclerotic plaque. On the other hand, the high-
density lipoprotein cholesterol (HDL) promotes reverse 
transport of cholesterol from lipid-laden macrophages in 
the vascular wall, and has anti-inflammatory effects, thereby 
inhibiting the progression of atherosclerosis and potentially 
inducing regression of the atherosclerotic plaque.7 In various 
conditions where levels of LDL are abnormally high or levels 
of HDL are low, the atherosclerotic process is enhanced, 
increasing the risk of development of CVD.
Statins exert their LDL-lowering effect primarily through 
the inhibition of the HMG-CoA-reductase enzyme, which 
mediates the first committed step in the mevalonate pathway 
of cholesterol synthesis. To a lesser degree, these agents also 
decrease triglyceride levels, probably through inhibition of its 
synthesis in the liver and enhancement of lipoprotein lipase 
enzyme activity in the adipocytes.8 Statins also have modest 
HDL-raising properties, which are postulated to result from 
the activation of peroxisome proliferator-activated   receptors, 
leading to Apo-A1 gene induction.9 It is also theorized 
that lipid-independent effects of statins contribute to some 
degree to their anti-atherothrombotic properties. A few of 
these purported pleiotrophic effects include modulation of 
  inflammatory response, improvement of endothelial function, 
and inhibition of coagulation.10
The earliest statin commercially developed,   lovastatin, 
was released for clinical use in 1987. Several other agents 
have been marketed since. Clinical data for some of the 
older statins (eg, lovastatin, pravastatin, simvastatin) showed 
  reductions of 25%–39% in LDL and 8%–12% in   triglycerides, 
as well as a 6%–8% increase in HDL. More potent agents 
(eg, atorvastatin, rosuvastatin) were later   developed,   making 
it possible to achieve even more   stringent target lipid 
goals (up to 55% reduction in LDL, up to 20% lowering in 
  triglycerides, and up to 10% increase in HDL).11,12
Statins in the primary  
prevention of CHD
Because atherogenic lipoproteins are involved very early in 
the atherosclerotic process, it is conceivable that   treatment 
with statins could potentially obviate the first onset of CHD 
events in individuals who are at risk but have not had a 
  previous coronary event. Indeed, analysis of data from 
primary prevention studies13 showed that statin therapy, on 
average, reduces the risk of overall mortality by 7% and MI 
by 27% (see Figure 1).
In patients with elevated cholesterol levels but without 
prior history of MI or stroke, the benefit of treatment with 
statins in the primary prevention of CHD was assessed by the 
West of Scotland Coronary Prevention Study (WOSCOPS)14 
and the more recent Management of Elevated Cholesterol in 
the Primary Prevention Group of Adult Japanese (MEGA)15 
trial. With an aggregate sample size of over 14,500 people, in 
both studies it was demonstrated that pravastatin was asso-
ciated with reductions in MI (31% in WOSCOPS, 48% in 
MEGA) and mortality (32% in WOSCOPS, 28% in MEGA) 
after 5 years of follow-up.
In individuals who have moderate cholesterol levels and 
are free of overt CVD, statin therapy using lovastatin was 
associated with reductions in major CHD events by 64% in the 
Asymptomatic Carotid Artery Progression Study (ACAPS)16 
and 37% in the Air Force/Texas Coronary   Atherosclerosis 
Prevention Study (AFCAPS/TexCAPS). Similarly, in over 
10,300 patients with average cholesterol profile and moderate 
CVD risk, the lipid-lowering arm of the   Anglo-  Scandinavian 
Cardiac Outcomes Trial (  ASCOT-LLA)17 found that 
  low-dose atorvastatin therapy resulted in a 36% reduction 
in fatal CHD and nonfatal MI.
In a primary prevention study of nearly 18,000 healthy 
participants with normal cholesterol profiles but elevated 
C-reactive protein levels, the Justification for the Use of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Statins in Prevention: an Intervention Trial Evaluating 
  Rosuvastatin (JUPITER)18 found that treatment with the agent 
rosuvastatin led to a 54% reduction in MI and 20% mortality 
reduction in this group of low-risk individuals. How the results 
of the JUPITER trial impact the current and future standards 
of clinical preventive therapy remains to be seen.
Lipid-lowering guidelines published before the comple-
tion of the JUPITER trial recommend that for primary pre-
vention of CHD in low-risk patients, statin therapy should 
be started if LDL is above 190 mg/dL, and is only optional if 
LDL . 160 mg/dL. Pharmacologic treatment is otherwise not 
advocated for healthy individuals with LDL , 160 mg/dL, 
unless two or more CVD risk factors are present.19 To date, 
there remains no consensus as to the clinical benefit of start-
ing maintenance statin treatment in low-risk, normocholes-
terolemic individuals.
Statins in the secondary  
prevention of CHD
While the debate continues as to whether or not healthy 
individuals should be treated with statins as a primary pre-
ventative measure, the role of statin therapy in the secondary 
prevention of further CHD events is unquestioned, and has, in 
fact, revolutionized the medical management of patients with 
preexisting CVD. The Scandinavian Simvastatin Survival 
Study (4S)20 was the first large clinical trial to demonstrate 
such benefit. In this study of 4,444 patients with established 
CHD, long-term treatment with simvastatin was shown to 
significantly reduce rates of mortality by 30% and coronary 
events by 34%. This was followed by the Cholesterol and 
Recurrent Events (CARE) trial, in which a 24% decrease in 
CHD events with pravastatin was found in over 4,000 patients 
with prior MI.21
The mortality benefit of statin therapy was unclear in 
the CARE trial, but this was definitively established by the 
Long-Term Intervention with Pravastatin in Ischemic Disease 
(LIPID)22 study of over 9,000 patients with unstable CHD. In 
this trial, pravastatin lowered the overall mortality by 14% and 
cardiovascular mortality by 24%, along with a 29% reduction in 
MI. The survival advantage of statin therapy was consistent, irre-
spective of baseline cholesterol level, as illustrated by the Heart 
Protection Study23 involving over 20,500 high-risk patients with 
CVD. In this trial, simvastatin was associated with significant 
reductions in all-cause mortality by 13% and in cardiovascular 
mortality by 18%, across a wide range of initial LDL levels.
High-dose statin therapy is associated with significantly 
greater reduction in the rate of progression of atherosclerosis 
compared to a moderate-intensity regimen in patients with 
CHD and elevated LDL.24 The benefits conferred by intensive 
statin therapy extends even to those with normal LDL levels, 
as seen in the Treat to New Targets (TNT) trial, where in over 
10,000 patients with CHD and LDL , 130 mg/dL, high-dose 
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atorvastatin therapy was superior to low-dose treatment in 
preventing recurrent CHD events.25
In patients with acute coronary syndrome (ACS), the 
Myocardial Ischemia Reduction with Aggressive Cholesterol 
Lowering (MIRACL)26 study showed that statin therapy 
using high-dose atorvastatin significantly lowered early 
recurrent ischemic events by 24%. Also, in the Pravastatin or 
Atorvastatin Evaluation and Infection Therapy-Thrombolysis 
In Myocardial Infarction 22 (PROVE IT-TIMI 22)27 trial it 
was found that intensive therapy using high-dose atorvastatin 
was superior to moderate-intensity treatment using pravas-
tatin in preventing subsequent CHD events in this high-risk 
group of patients with ACS.
A meta-analysis of 25 trials involving nearly 70,000 
patients with CHD found that statin therapy, on average, 
reduces CVD events by 25% and overall mortality by 16%, 
irrespective of pretreatment lipid levels, including those with 
baseline LDL below 100 mg/dL (see Figure 2).28
The prevailing secondary prevention guidelines for 
patients with established CHD recommend prompt   initiation 
of statin therapy to achieve a goal LDL , 100 mg/dL, using 
an intensity sufficient enough to achieve a 30%–40% 
LDL reduction in high-risk individuals. A target LDL 
goal ,70 mg/dL using high-dose statin treatment is also 
considered desirable.29 Additionally, in patients with 
ACS,   including those who underwent revascularization, it 
is strongly advocated that statin therapy be started regardless 
of baseline LDL levels.30
Statins and cerebrovascular disease
In addition to the significant reduction in CHD risk, there 
is also evidence pointing to the advantages of statin therapy 
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in the primary prevention of stroke. Statin treatment was 
associated with a 27% reduction in stroke in high-risk patients 
enrolled in the ASCOT-LLA primary prevention study. 
Among low risk patients, on the other hand, statin therapy 
was associated with a 51% reduction in ischemic stroke in 
the JUPITER primary prevention trial.31
There are ample data supporting the benefit of statin 
therapy in the secondary prevention of cerebrovascular events 
as well. In over 4,700 patients with recent stroke or transient 
ischemic attack (TIA), in the prospective, randomized Stroke 
Prevention by Aggressive Reduction in Cholesterol Levels 
(SPARCL) trial32 it was found that treatment with high-dose 
atorvastatin was associated with significant reductions in 
the incidence of recurrent stroke by 16% and CVD events 
by 20%. In a large registry of patients with ischemic stroke, 
pretreatment with statins was associated with a 40% reduction 
in the odds of poor outcome after stroke in Whites. The same 
effect, however, was not demonstrated in Blacks.33 In elderly 
individuals with CVD, statin therapy reduced the incidence 
of TIA by 25% in the PROSPER trial, although the overall 
stroke risk was unaffected.
Pooled data from the LIPID, CARE, and WOSCOPS 
trials, involving nearly 20,000 patients with CHD, showed 
that pravastatin therapy reduced the total stroke risk by 22% 
across a wide range of lipid values.34 More recently, the TNT 
trial demonstrated a 25% reduction in fatal and nonfatal 
strokes in CHD patients treated with high-dose compared to 
low-dose atorvastatin. Also, in patients with ACS, a substudy 
of the MIRACL trial found that short-term treatment with 
atorvastatin was associated with a significant 50% reduction 
in fatal and nonfatal strokes.35
Recommendations on specific target lipid goals and 
initiation of statin therapy in the primary prevention of cere-
brovascular events are the same as that of CHD.36 Statins are 
strongly recommended in patients with stroke or TIA and 
co-morbid CHD to achieve a target LDL goal , 100 mg/dL, 
and LDL , 70 mg/dL for very high-risk individuals with 
multiple risk factors. In stroke or TIA patients without 
concomitant CHD or hyperlipidemia, initiation of statin 
therapy is considered reasonable for prevention of subsequent 
CVD events.37
Statins and heart failure
Retrospective analyses of landmark clinical trials on lipid-
lowering therapy have pointed to the potential beneficial 
effect of statins in the setting of HF. The earliest clinical 
data suggesting such effect came from the post-hoc analysis 
of the 4S trial, in which in patients with CHD but without 
symptomatic HF, simvastatin therapy was associated with a 
lower incidence of subsequent development of symptomatic 
HF compared to placebo. In patients with preexisting HF, 
statin therapy was also linked to a 19% reduction in mor-
tality.38 Similarly, a substudy of the Treating to New Targets 
(TNT) trial which enrolled 10,000 patients with stable CHD 
demonstrated that high-dose statin therapy (atorvastatin 
80 mg daily) resulted in a 26% risk reduction in hospitaliza-
tion for HF compared to low-dose atorvastatin (10 mg daily). 
This effect was even more prominent (41% risk reduction) 
in people who had history of HF.39
In patients with known CHD and ischemic HF, analy-
sis of data from the Multicenter Automatic Defibrillator 
Implantation Trial (MADIT-II) showed that those who used   
statin $ 90% of the time had a 35% lower incidence of ven-
tricular arrhythmias or cardiac death compared to participants 
who took statins less often.40 In patients with nonischemic 
cardiomyopathy, on the other hand, a substudy of the Defibril-
lators in Non-Ischemic Cardiomyopathy Treatment Evalua-
tion (DEFINITE) trial found a 22% decrease in appropriate 
defibrillator shocks and an 84% reduction in arrhythmic 
sudden death in participants treated with a statin.41
However, large, prospective, randomized trials failed 
to corroborate these findings. For instance, the Controlled 
Rosuvastatin Multinational Trial in Heart Failure (CORONA) 
involving over 5,000 elderly patients with ischemic HF, 
found no significant beneficial effect of statin treatment with 
rosuvastatin on risk reduction of CVD events.42 Likewise, 
rosuvastatin treatment had a similar influence as placebo in 
terms of CVD outcomes in over 4,500 patients with ischemic 
and non-ischemic HF enrolled in the GISSI-HF trial.43
Given the lack of definitive evidence, existing heart 
failure guidelines do not specifically address the role of 
statins in heart failure therapy. However, these guidelines 
do recommend that patients with other concomitant CVD 
(eg, hyperlipidemia, diabetes or CHD) be treated according 
to current standards of care.44 In this context, statin therapy 
should be utilized in patients with HF if there are any 
comorbid conditions requiring its use.
Statins and peripheral vascular 
disease
Post-hoc analysis of the Heart Protection Study provided 
one of the earliest reliable data sets for the beneficial effects 
of statin therapy in PVD. In over 6,700 patients with known 
PVD enrolled in the trial, statin therapy using simvastatin was 
found to be associated with a 22% reduction in CVD events 
and a 20% decrease in noncoronary revascularization, effects Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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which appeared to be independent of baseline cholesterol lev-
els.45 Small, non-randomized studies also showed that statin 
use in patients with PVD was linked to significant improve-
ments in walk performance and overall leg function.46,47 
Pleitrophic effects of statins have been postulated to be 
responsible for these effects, as the findings appeared to be 
independent of cholesterol-lowering.
Randomized trials in which a small number of patients with 
PVD and intermittent claudication were enrolled also demon-
strated improvements in overall walking performance, ankle-
brachial pressure indexes, and symptoms of claudication with 
statin therapy. Short-term (6 months) treatment with statins, 
on average, increased pain-free walking distance by 90 meters 
and symptom-free exercise time by nearly 1 minute.48–50
Still lacking, however, are large, multicenter, randomized 
trials that are adequately powered to confirm the therapeu-
tic advantage of statins on both CVD outcomes as well as 
symptom/quality-of-life measures. Since this condition is 
considered a CHD-equivalent, existing guidelines recommend 
the use of statin therapy to prevent CVD events in all patients 
with PVD to achieve a target LDL , 100 mg/dL, or lower 
(,70 mg/dL) in those with lower extremity PVD at very high 
risk for ischemic events.51 The role of lipid-lowering therapies 
for treatment of claudication symptoms, however, has yet to 
be established.
Use of statins in diabetes mellitus
Early studies on lipid-lowering therapy raised the possibility 
of a beneficial effect of statins on CVD events in patients with 
diabetes. Meta-analysis of the LIPID, CARE, and 4S trials 
found that in diabetic patients, statin therapy was associated 
with a 28% reduction in coronary events and a 32% reduction 
in stroke, across a wide range of baseline cholesterol levels. 
The protection from CVD events seen with statins was greater 
for patients with diabetes than the non-diabetics.52
The Heart Protection Study provided the first direct 
evidence that statin therapy produces reductions in CVD 
events among people with diabetes.53 It was found that among 
nearly 6,000 patients with known diabetes, treatment with 
simvastatin was associated with a 22% reduction in coronary 
events and strokes, irrespective of comorbid CVD conditions 
and baseline LDL levels.
The effectiveness of statin therapy in the primary pre-
vention of CVD in patients with diabetes was subsequently 
established by the Collaborative Atorvastatin Diabetes Study 
(CARDS).54 In this trial of over 2,800 diabetic patients with 
average cholesterol levels and without preexisting CVD, 
treatment with atorvastatin led to reductions in CHD events 
by 36%, stroke by 48%, and mortality by 27%.
Current clinical practice standards recommend statin therapy 
to achieve an LDL goal , 100 mg/dL in most patients with 
diabetes. In those with overt CVD, statin therapy is encouraged 
regardless of baseline lipid levels, with LDL , 70 mg/dL listed 
as a reasonable goal in these patients.55
Statins and chronic kidney disease
In over 1,700 CHD patients enrolled in the CARE trial with 
concomitant mild renal dysfunction, statin therapy using 
pravastatin was associated with a 28% reduction in coronary 
events.56 In a similar subset of patients in the 4S trial, simvas-
tatin treatment was associated with decreases in CHD events 
by 33% and in mortality by 31%.57 Of particular note, statin 
therapy did not appear to reduce the incidence of stroke in 
these studies of patients with mild CKD.
Patients with moderate CKD were shown to have nearly 
50% higher risk of CVD events compared to those with 
normal renal function or mild CKD. In a subgroup analysis 
of the MEGA study, reduction in the incidences of CHD by 
48%, stroke by 73%, and mortality by 51% were seen with 
pravastatin therapy in patients with moderate CKD.58
A recent meta-analysis of 26 trials involving over 25,000 
patients with CKD not requiring dialysis found a significant 
mortality reduction with statin therapy without an increase 
in adverse events.59 However, this benefit did not appear to 
extend to those with end-stage CKD. The prospective German 
Diabetes and Dialysis Study (GDDS) randomized over 1,200 
diabetic patients on maintenance dialysis to treatment with 
either atorvastatin or placebo. After 4 years of follow-up, 
no beneficial effect on CVD events or mortality was seen 
with atorvastatin therapy. Although statin therapy led to a 
modest 18% reduction in combined cardiac events, this was, 
however, negated by a 2-fold increase in the incidence of fatal 
stroke.60 A similar conclusion was made by the AURORA 
(A Study to Evaluate the Use of Rosuvastatin in Subjects 
on Regular Hemodialysis: An Assessment of Survival and 
Cardiovascular Events) trial, where rosuvastatin treatment 
showed no significant influence in terms of CHD, stroke, 
or mortality risk reduction in patients undergoing dialysis, 
despite a 43% lowering in LDL.61 It is thought that the 
initiation of lipid-lowering therapy in patients who already 
have end-stage renal disease may be too late to translate into 
consistent improvement of outcomes.
The National Kidney Foundation guidelines classify all 
stages of CKD as CHD-equivalent, and recommend that all 
patients with CKD be treated to a target LDL , 100 mg/dL. 
Statin is the initial preferred agent if baseline LDL is above 
130 mg/dL or in patients with Stage 5 CKD (kidney failure 
or clinical indication for dialysis or transplantation).62Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Compliance to statins  
in the real world
Despite the well-established benefits and abundance of 
clinical management guidelines strongly advocating statin 
use in high-risk cardiac conditions, long-term adherence to 
statin regimens in patients who are appropriate candidates 
has generally been poor, and continued use of statins drops 
substantially over time. In the WOSCOPS trial, for example, 
less than 40% of patients in the original statin group were 
on a statin 5 years after the study ended.63 In one series, 
the greatest decline occurred during the first 6 months, and 
only 25% of patients maintained an acceptable level of com-
pliance to statins 5 years after initiation of therapy.64
In patients with CHD, in a recent survey a 26% rate of 
noncompliance to statins was found, which was in turn asso-
ciated with an 85% increase in overall mortality.65 Among 
those who had ACS, the continuation rate for statin drops to 
44% after 3 years.66 Similarly, the stroke survivors’ adher-
ence to recommended statin regimens rapidly declines after 
hospital discharge, and barely half of these patients remain 
on treatment after 2 years.67 Diabetics are not faring any bet-
ter, with less than half of patients maintaining a satisfactory 
degree of long-term statin adherence.68
The causes for noncompliance are multifactorial. One of 
the major reasons is the unfounded fear by patients and phy-
sicians alike regarding the toxicity of lipid-lowering agents. 
A major contributor to this anxiety is the glut of information 
on the Internet on the adverse effects of statins. Such safety 
concerns, however, are obviously not supported by recent large 
randomized trials (see Figure 3). Although myalgia without 
any CPK rise can occur in up to 5% of statin users, which 
might be perceived as a side effect, serious adverse events are 
rare, and statin-induced rhabdomyolysis occurs in less than 1 
per 100,000 patients exposed.69 Another explanation for the 
nonadherence of patients to statin therapy is the lack of educa-
tion and awareness about the long-term benefits of treatment, 
especially since they do not feel better right away.
Younger age, female gender, black or hispanic ethnicity, 
higher comorbidity, and lower median income were some of 
the patient-related predictors of nonadherence to prescribed 
statin regimen.70 Among physician-related factors, patients 
were more likely to comply if the statin was prescribed by 
a cardiologist or a primary care doctor.71 All these factors 
need to be considered in devising approaches to enhance 
adherence to guideline-based therapies.
Interventions to increase  
adherence to statin regimen
It is now well-established that the use of statins is associated 
with lower mortality, and prolongs the lifespan by an average 
of 2 years, even if therapy is initiated at a more advanced 
age.72 For patients to reap the full protective benefits of statin 
therapies, however, it is obvious that overall compliance to 
such regimen needs to be improved.
In individuals and patient groups who are more likely to 
discontinue treatment, perhaps a more intensive educational 
Cancers
Rhabdomyolysis
0.2 0.5
Relative risk (95% confidence interval)
12 5
0.97 (0.25, 3.83)
1.02 (0.94, 1.11)
Relative risk (95% Cl)
Figure 3 Plotted estimates of adverse events cancer and rhabdomyolysis pooled from primary prevention trials on statin therapy. Pooled relative risk with bars representing 
95% confidence intervals (CIs). 
Notes: Adapted with permission from Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: 
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program (highlighting the safety, and long-term benefits with 
achieved target LDL) and closer monitoring of   compliance 
could be used to ensure sustained long-term statin use. 
The utilization of statins by patients has been shown to 
be dynamic, with over half of new statin users having periods 
of nonadherence lasting at least 90 days. Regular clinical 
follow-up visits and serial lipid testing appear to promote 
reinitiation of therapy in one study,73 and can be one of the 
simpler interventions clinicians can employ to promote long-
term statin adherence in most patients.
A multidisciplinary disease-management team approach 
to patient management has also been shown to improve com-
pliance to statins and other guideline-based therapies. In a 
single-center interventional program for patients who under-
went coronary artery bypass surgery, a quality improvement 
team consisting of thoracic surgeons, clinical pharmacists, 
dieticians, physical therapists, and nurse coordinators, imple-
mented a goal-directed approach to postoperative care, which 
resulted in a significantly higher adherence to recommended 
therapies on hospital discharge.74 This is important since it 
is known that prescription for statins at the time of hospital 
discharge enhances long-term statin compliance.75 A similarly 
structured cardiac rehabilitation program may also exert a 
favorable impact on the sustained adherence to statins and 
other essential medications in the outpatient setting.76
Another possible reason for poor utilization of statins is 
that some healthcare providers may fail to prescribe them 
in appropriate patients. Hence, compliance to the recom-
mended therapies by physicians needs to be addressed as 
well. National and institution-based initiatives to promote 
adherence to guideline-based therapies, including statin 
utilization, in high-risk CVD patients have been shown to be 
effective and have resulted in improved outcomes. Among 
those successfully implemented include the Get-With-The-
Guidelines (GTWG) initiative, the Guidelines Applied in 
Practice (GAP) project, and the Cardiac Hospitalization 
Atherosclerosis Management Program (CHAMP).
CHAMP, which was initiated at a large university hospital, 
implemented a simplified treatment algorithm that focused 
improving utilization of statins and other guideline-based thera-
pies before hospital discharge in patients with CHD. Compari-
son of outcomes before and after the program started showed 
that CHAMP was associated with a significant increase in use 
of recommended medications, and an increase in the proportion 
of patients achieve target lipid goals, which subsequently led to 
significant reductions in recurrent MI and mortality.77
The GAP project was promoted by the American College 
of Cardiology and was adopted by 33 participating hospitals. 
The program aimed to foster systems-based hospital care of 
ACS patients from admission to discharge, incorporating stan-
dard, evidence-based tools into practice and targeting patients, 
physicians, and nurses. In hospitalized patients with ACS, the 
improved adherence to statins and other guideline-based thera-
pies associated with the project was demonstrated to result in 
significant lowering of short-term and long-term mortality.78
The GTWG quality improvement initiative, on the other 
hand, was implemented by the American Heart Association 
to optimize and standardize the hospital care for patients 
with CHD, stroke, and HF. In nearly 1,500 voluntarily-
  participating hospitals, this program has improved the 
compliance to recommended therapies in the inpatient 
setting, which translated to improvement in CVD outcomes.79 
In patients with high-risk CVD, adherence to GWTG quality 
measures has eliminated or at least diminished the age-, 
gender-, racial-, and ethnicity-related disparities in hospital 
care.80–82 The benefits of participation in the GTWG program 
have also been shown to persist over time, independent of 
hospital characteristics.83
Initiatives like the GTWG are excellent models by which to 
pattern interventions to enhance statin compliance, especially if 
such programs are expanded to include the outpatient and gen-
eral community setting. From a regulatory perspective, the core 
measures and the accreditation standards set forth by the Joint 
Commission on Accreditation of Healthcare Organizations 
(JCAHO) for MI, HF, stroke, and CKD are another powerful 
venue where utilization of guideline-based therapies can poten-
tially be enhanced. Inclusion of the use of statins in the JCAHO 
quality measures for these patients with high-risk CVD would 
certainly improve adherence to such agents.
Higher drug prescription co-payment costs and insurance 
cost-sharing schemes adversely affect adherence to lipid-
lowering therapies. In high-risk patients who need statins the 
most, full out-of-pocket spending for drug prescription nearly 
doubles the likelihood of stopping treatment.84 On a broader 
economic perspective, elimination of out-of-pocket costs 
may be an appropriate, cost-effective public health strategy 
(by reducing the need for hospitalization and expensive pro-
cedures) to enhance long-term compliance to statin therapy. 
While an increase in statin utilization might increase drug-
related expenditure in the short term, this is counterbalanced 
eventually by the expected benefits in terms of mortality and 
morbidity reduction. In a recent Medicare cost-effectiveness 
model analysis, it was projected that full drug coverage for 
secondary prevention therapies would result in greater func-
tional life expectancy and less resource utilization, a move 
that appears highly cost-effective in the long term.85Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Conclusion
An overwhelming amount of data that confirm the morbid-
ity and mortality benefit of statin therapy in high-risk CVD 
conditions have been reported, both in the primary and 
secondary prevention settings. National and international 
clinical guidelines in the management of CHD, stroke, 
diabetes, CKD, CHF, and PVD all advocate the utilization 
of statin therapy in appropriate patients. However, overall 
compliance to statin therapy remains suboptimal. Patient-, 
physician-, and economic-related factors all play a role. 
These factors need to be considered in devising approaches 
to enhance adherence to guideline-based therapies. To fully 
benefit from the potential of these agents, interventions which 
improve long-term treatment compliance in real-world set-
tings should be encouraged.
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